DALLAS, July 22, 2009 (GLOBE NEWSWIRE) -- InvestorSoup.com announces an investment report featuring specialty pharmaceutical company Labopharm Inc. (Nasdaq:DDSS). The report includes financial and investment analysis, analyst consensus, and pertinent industry information you need to know to make an educated investment decision.
The investment report on Labopharm Inc. (Nasdaq:DDSS) should be of particular interest to other drug companies: Depomed Inc. (Nasdaq:DEPO), Biovail Corp. (NYSE:BVF), Watson Pharmaceuticals Inc. (NYSE:WPI) and Impax Laboratories Inc. (Nasdaq:IPXL).
It is available at: http://www.investorsoup.com/lp/DDSS
Get our alerts BEFORE the rest of the market. Follow us on Twitter: www.twitter.com/investorsoup
Labopharm Inc. (DDSS) is an international specialty pharmaceutical company focused on improving existing drugs by incorporating its advanced controlled-release technologies. The Company develops products internally in order to enter into strategic alliances or licensing agreements with national or international pharmaceutical companies that have the necessary resources and distribution networks to market and sell its pharmaceutical products.
In the report, the analyst notes:
"In addition, it has received regulatory approval or is under regulatory review in 29 countries and the Company has established marketing partnerships for its product in 38 countries. Meanwhile, DDSS' product (marketed under the brand name Tridural in Canada) was ranked number one among tramadol products in terms of new-to-brand prescriptions in Canada for the first quarter of 2009.
"In April 2009, DDSS completed North American phase III clinical trial for its third product - a twice-daily formulation of tramadol and acetaminophen. The twice-daily formulation of tramadol plus acetaminophen is designed to provide both immediate and sustained relief of moderate to severe pain."
To read the entire report visit: http://www.investorsoup.com/lp/DDSS
InvestorSoup.com is a small-cap research and investment commentary provider. InvestorSoup strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on InvestorSoup, please visit http://www.InvestorSoup.com
InvestorSoup Disclosure
InvestorSoup.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. InvestorSoup.com is a Web site wholly-owned by BlueWave Advisors, LLC. Please read our report and visit our Web site, InvestorSoup.com, for complete risks and disclosures.
CONTACT: InvestorSoup.com
Jeffrey Brown, Editor
(469)-252-3505
info@investorsoup.com
